Pilot Introduction of Oral Cholera Vaccine in Orissa, India

Learn more about:
Related Clinical Trial
Preventative Intervention for Cholera for 7 Days Impact Study of Cholera Vaccination in Endemic Areas – Clinical Surveillance Water, Sanitation, and Hygiene Mobile Health Messages as an Innovative Tool to Facilitate Behavior Change Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™ in Nepalese Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults PXVX0200 (CVD103-HgR) vs Shanchol in Mali Cholera-Hospital-Based-Intervention-for-7-days A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Adults Follow-up of Pregnant Women After a Mass Vaccination of Oral Cholera Vaccine (ShancholTM) in Nsanje Malawi Single Dose Azithromycin in the Treatment of Adult Cholera Safety and Immunogenicity of a New Formulation of Euvichol® Cholera Anti-Secretory Treatment Trial PK Study of iOWH032 in Adult Male/Female Healthy Volunteers & Adult Males With Cholera Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine Zinc Supplementation in Cholera Patients Immunologic Responses to a Live Attenuated Oral Cholera Vaccine Pilot Introduction of Oral Cholera Vaccine in Orissa, India Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200 Immunity to Human Cholera in Bangladesh Ciprofloxacin Multiple Dose for Adult Cholera Effect of Probiotic on Immunogenicity of Oral Cholera Vaccine Effectiveness of a Bivalent Killed Whole Cell Based Oral Cholera Vaccine Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera Impact Evaluation of Urban Water Supply Improvements on Cholera and Other Diarrhoeal Diseases in Uvira, Democratic Republic of Congo Protective Immunity to Human Cholera in Bangladesh Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine Oral Cholera Vaccine Delivery in Rural Bangladesh Study of Alternative Vaccination Schedule of Oral Cholera Vaccine Mass Oral Cholera Vaccination in Zanzibar Cholera Vaccine Investment Strategy in Bangladesh Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine Bridging Study for Killed Oral Cholera Vaccine in Ethiopia Safety and Immunogenicity of Locally Manufactured Oral Cholera Vaccine Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in Dominican Republic Introduction of Cholera Vaccine in Bangladesh Evaluation of a Pilot Program to Introduce Cholera Vaccine in Haiti as Part of Global Cholera Control Efforts Single Dose Oral Cholera Vaccine Study in Dhaka, Bangladesh Evaluation of a Boosting Regimen With Oral Cholera Vaccine Single Dose Azithromycin to Prevent Cholera in Children Safety and Immunogenicity of Oral Cholera Vaccine in Kolkata A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines Randomized Controlled Trial of Killed Oral Cholera Vaccine in Kolkata

Brief Title

Pilot Introduction of Oral Cholera Vaccine in Orissa, India

Official Title

Pilot Introduction of the Modified Bivalent Killed Whole Cell Oral Cholera Vaccine in Orissa

Brief Summary

      The purpose of this study is to provide evidence for policymakers and key opinion leaders on
      the pilot implementation of cholera vaccination using the newly licensed Oral Cholera Vaccine
      (OCV) in India. The pilot introduction will provide the evidence for the feasibility, costs
      and population acceptance of large-scale cholera vaccination using the Indian vaccine (using
      vaccination coverage rates and other measures).

Detailed Description

      Severe diarrhoeal disease caused by Vibrio cholerae O1 and O139 has long been an important
      cause of mortality and morbidity in India. The availability and recent licensure of the
      modified bivalent killed whole cell OCV in India provides hope that the disease may be
      controlled in areas where the disease is a problem. On April 10, 2009, a meeting was
      organized by the Indian Council of Medical Research (ICMR), the Department of Biotechnology
      and the IVI. The recommendations from the meeting are as follows:

        -  As the modified WC vaccine is safe, effective, and cost-effective, it was suggested that
           the National Technical Advisory Group on Immunization (NTAGI) should consider
           recommending introduction of the vaccine in public health programs targeted to
           appropriate populations in India.

        -  Vaccination should be initiated in selected highly endemic and/or slum areas such as
           known areas in West Bengal or Orissa. The pilot vaccination programs will be monitored
           and evaluated. Further expansion to other areas and wider policy changes will be made in
           a step-by-step fashion based on the pilot programs. Logistical and operational issues
           need to be defined.

      The aim of the study is to conduct a pilot introduction of the modified killed oral cholera
      vaccine in a public health setting in a population of ~50,000 before implementing in a larger

      Primary objective:

      To determine the feasibility, acceptability and costs associated with pilot introduction of
      the modified killed whole cell oral cholera vaccine in India when given in a public health

      Secondary objective:

      To identify challenges to mass oral cholera vaccine implementation.

Study Type


Primary Outcome

To determine the feasibility

Secondary Outcome

 Assessment of acceptability and costs of vaccination program



Study Arms / Comparison Groups

 Consenting, eligible participants
Description:  All consenting eligible participants in the study area will receive the oral cholera vaccine


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment


Start Date

May 2011

Completion Date

September 2012

Primary Completion Date

March 2012

Eligibility Criteria

        Inclusion Criteria:

          -  aged 12 months and older

          -  non-pregnant

        Exclusion Criteria:

          -  age less than 12 months

          -  pregnant

          -  too ill/old to get out of bed




12 Months - N/A

Accepts Healthy Volunteers

Accepts Healthy Volunteers


Shantanu K Kar, MD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

International Vaccine Institute


 Department of Health and Family Welfare, Orissa

Study Sponsor

Shantanu K Kar, MD, Principal Investigator, Director, Regional Medical Research Center, Bhubaneswar, Orissa, India

Verification Date

May 2013